1[1]Erkeller-Yuksel FM, Deneys V, Yuksel B, et al. Age-related changes in human blood lymphocyte subpopulations[J]. J Pediatr, 1992, 120: 216-222.
2[2]Wever PC, Boonstra JG, Laterveer JC, et al. Mechanisms of lymphocyte mediated cytotoxicity in acute renal allograft rejection [J]. Transplantation, 1998, 66:259-264.
3[3]Peng SL, Moslehi J, Robert ME, et al. Perforin protects against autoimmunity in lupus-prone mice [J]. J Immunol, 1998, 160:652-660.
4[4]Gebhard JR, Perry CM, Harkins S, et al. Coxsackievirus B3 induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance [J]. Am J Pathol, 1998, 153:417- 428.
5[5]Kagi D, Vignaux F, Ledermann, et al. Fas and perforin as major mechanism of T cell-mediated cytotoxicity [J]. Science, 1994, 265:528-532.
6[6]Lowin B, Hahne M, Matcmann C, et al, Cytolytic T cell cytotoxicity is mediated through perforin and Fas lytic pathways [J]. Nature, 1994, 370:650.
7[7]Rukavina D, Laskarin G, Rubesa G, et al. Age-related decline of perforin expression in human cytotoxic T lymphocytes and natural killer cells[J]. Blood, 1998, 92:2410-2420.
8[8]Berthou C, Bourge JF, Zhang Y et al. Interferon-γ-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis[J]. Blood, 2000, 95:2329-2336.
9[9]Lehmann C, ZeisM, Schmitz N, et al. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells[J]. Blood. 2000, 96: 594-600.
